BMC Psychiatry (Sep 2022)

The clinical course of comorbid substance use disorder and attention deficit/hyperactivity disorder: protocol and clinical characteristics of the INCAS study

  • Christoffer Brynte,
  • Myriam Aeschlimann,
  • Csaba Barta,
  • Alex Hendikus Abraham Begeman,
  • Amanda Bäcker,
  • Cleo Lina Crunelle,
  • Constanza Daigre,
  • Laura De Fuentes-Merillas,
  • Zsolt Demetrovics,
  • Geert Dom,
  • Lara Grau López,
  • Romain Icick,
  • Brian Johnson,
  • Peter Joostens,
  • Máté Kapitány-Fövény,
  • Emily Karsinti,
  • Falk Kiefer,
  • Maija Konstenius,
  • Frances R. Levin,
  • Mathias Luderer,
  • Wiebren Markus,
  • Frieda Matthys,
  • Franz Moggi,
  • Raul Felipe Palma-Alvarez,
  • Maria Paraskevopoulou,
  • J. Antoni Ramos-Quiroga,
  • Arnt Schellekens,
  • Leila M. Soravia,
  • Norman Therribout,
  • Anil Thomas,
  • Geurt van de Glind,
  • Michiel Willem van Kernebeek,
  • Sabine Vollstädt-Klein,
  • Florence Vorspan,
  • Wim van den Brink,
  • Johan Franck

DOI
https://doi.org/10.1186/s12888-022-04259-6
Journal volume & issue
Vol. 22, no. 1
pp. 1 – 8

Abstract

Read online

Abstract Background Substance use disorders (SUD) often co-occur with attention deficit hyperactivity disorder (ADHD). Although the short-term effects of some specific interventions have been investigated in randomized clinical trials, little is known about the long-term clinical course of treatment-seeking SUD patients with comorbid ADHD. Aims This paper presents the protocol and baseline clinical characteristics of the International Naturalistic Cohort Study of ADHD and SUD (INCAS) designed and conducted by the International Collaboration on ADHD and Substance Abuse (ICASA) foundation. The overall aim of INCAS is to investigate the treatment modalities provided to treatment-seeking SUD patients with comorbid ADHD, and to describe the clinical course and identify predictors for treatment outcomes. This ongoing study employs a multicentre observational prospective cohort design. Treatment-seeking adult SUD patients with comorbid ADHD are recruited, at 12 study sites in nine different countries. During the follow-up period of nine months, data is collected through patient files, interviews, and self-rating scales, targeting a broad range of cognitive and clinical symptom domains, at baseline, four weeks, three months and nine months. Results A clinically representative sample of 578 patients (137 females, 441 males) was enrolled during the recruitment period (June 2017-May 2021). At baseline, the sample had a mean age (SD) of 36.7 years (11.0); 47.5% were inpatients and 52.5% outpatients; The most prevalent SUDs were with alcohol 54.2%, stimulants 43.6%, cannabis 33.1%, and opioids 14.5%. Patients reported previous treatments for SUD in 71.1% and for ADHD in 56.9%. Other comorbid mental disorders were present in 61.4% of the sample: major depression 31.5%, post-traumatic stress disorder 12.1%, borderline personality disorder 10.2%. Conclusions The first baseline results of this international cohort study speak to its feasibility. Data show that many SUD patients with comorbid ADHD had never received treatment for their ADHD prior to enrolment in the study. Future reports on this study will identify the course and potential predictors for successful pharmaceutical and psychological treatment outcomes. Trial registration ISRCTN15998989 20/12/2019.

Keywords